Agilent Technologies (A) Rises +14.7% Over 30 Days: Momentum Builds Ahead of Earnings
Key Takeaways
- Agilent Technologies (A) climbed about 14.7% over the trailing 30 days, rising from roughly $138.57 to a close near $159.00.
- The advance pushed the stock to a new 52-week high of $160.51, extending a broader rally that began after its fiscal Q2 2026 earnings beat in late May.
- The move has been supported by analyst target increases, continued strength in semiconductor-driven demand, and positive sentiment in the life sciences tools sector.
- Wall Street carries a consensus "Moderate Buy" rating with an average price target near $160, reflecting confidence in the company's raised fiscal 2026 guidance.
- The company reports fiscal Q3 2026 results on August 26, a key catalyst investors are watching next.
Company Overview: Agilent Technologies (A) and Its Market Position
Agilent Technologies, Inc. is a global leader in analytical and clinical laboratory technologies, serving the life sciences, diagnostics, and applied chemical markets. Headquartered in Santa Clara, California, the company designs and manufactures instruments, software, services, and consumables used in pharmaceutical research, clinical diagnostics, environmental testing, food safety, and advanced materials.
Agilent operates primarily through two reporting segments: the Life Sciences and Diagnostics Group (LDG) and the Applied Markets Group (AMG). Its portfolio spans liquid chromatography and mass spectrometry systems, gas chromatography, spectroscopy, and a growing suite of digital and software offerings. With a market capitalization near $45 billion, diversified end markets, and a recurring services and consumables revenue stream, Agilent Technologies (A) is one of the most closely followed names in the analytical instruments and life sciences tools sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: Last 30 Days and the Broader Quarter
Over the trailing 30-day period, Agilent shares rose from a closing price of $138.57 on July 24, 2026, to approximately $159.00 by August 21, 2026, a gain of roughly 14.7%. The stock broke out of a multi-week consolidation range in early August and reached a new 52-week high of $160.51 on August 21, reflecting steadily improving investor conviction.
The move extends a substantially larger multi-month advance. Over the past quarter, Agilent shares climbed from around $115 in late May to roughly $159, an increase of approximately 38%. The bulk of that gain was driven by a sharp post-earnings rally following the company's fiscal second-quarter results, followed by a period of consolidation and a renewed push higher into late summer. From what I see, the consistency in volume during the breakout adds credibility to the move.
Drivers Behind the 30-Day Rally in Agilent (A)
Agilent's 30-day rally was driven by a combination of analyst actions, sustained end-market strength, and positioning ahead of its next earnings report. On August 12, Morgan Stanley raised its price target on Agilent to $175 from $160 while maintaining an Overweight rating, citing continued execution and product-cycle momentum. Other firms, including Leerink Partners and Evercore ISI, also maintained constructive ratings on the stock during the period.
Fundamentally, demand in the company's Applied Markets Group has remained a bright spot, with spectroscopy and semiconductor-related demand supporting growth in chemical and advanced materials. Agilent's accelerated launch of its 9500 triple quadrupole ICP-MS instrument and refreshed gas chromatography platforms have reinforced investor expectations for a durable replacement cycle and pricing power. The stock's breakout to new highs also reflected broader rotation into quality life sciences tools names and continued institutional accumulation, with institutional ownership near 87%. I’m watching this closely as the semiconductor exposure continues to resonate.
The Earnings Catalyst That Sparked the Quarterly Gains
The past quarter's gains trace back to Agilent's fiscal Q2 2026 results reported on May 27. The company posted revenue of $1.83 billion, up 10% year over year, with core growth of 6.3% that exceeded the high end of its guidance. Adjusted earnings per share rose 14% to $1.49, beating consensus by $0.08, while operating margin expanded 130 basis points to 26.4%. Shares surged nearly 17% the following day.
Management raised its full-year guidance to revenue of $7.39 billion to $7.49 billion and adjusted EPS of $6.00 to $6.10, reflecting confidence in its Ignite operating system and broad-based demand across pharma, diagnostics, and advanced materials. That beat and upgrade reset the stock's trajectory, and subsequent analyst target increases have helped sustain the rally into August.
What to Watch Next for Agilent Technologies (A)
Agilent's fiscal Q3 2026 earnings report, scheduled for August 26, is the most immediate catalyst. Management has guided for Q3 EPS of $1.48 to $1.50 on revenue of $1.83 billion to $1.85 billion, and investors will focus on core growth trends, margin trajectory, and any update to full-year guidance. Ongoing China-related funding delays and softer academia and government spending remain key risks to monitor.
Beyond earnings, watch the health of semiconductor-related demand within Applied Markets, the pace of new product adoption, and the durability of pricing gains under the Ignite program. Macroeconomic factors including tariffs, supply chain conditions, and broader capital-spending trends across pharma and diagnostics will also influence the stock's direction. One thing that stands out is how resilient the core growth has been despite those headwinds.
Using AI Tools in My Research Process
When evaluating stocks like this, I often cross-reference traditional analysis with algorithmic signals to confirm patterns and peer performance. Tickeron’s AI Trend Prediction Engine has been useful for spotting longer-term momentum shifts in the life sciences sector. In my view, combining these insights with fundamental data provides a more complete picture without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
A in upward trend: price may jump up because it broke its lower Bollinger Band on September 08, 2026
A may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 42 cases where A's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on A as a result. In 61 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for A just turned positive on September 18, 2026. Looking at past instances where A's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.
Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 186 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 123 of 203 cases where A Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 19 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.992) is normal, around the industry mean (60.700). P/E Ratio (30.862) is within average values for comparable stocks, (144.546). Projected Growth (PEG Ratio) (1.292) is also within normal values, averaging (3.432). A has a moderately high Dividend Yield (0.007) as compared to the industry average of (0.001). P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of measurement and monitoring instruments
Industry MedicalSpecialties
Advertisement